arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ALUMIS INC.

ALMS
$5.83 ▼ -0.72 (-11.05%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

ALUMIS INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $744.4M
Dividend Yield —
Revenue Growth -37.7% ↗
Op. Margin —
ROIC -32.5% ↘
FCF / Share $-0.64 ↗
Trailing P/E —
Price / Book 1.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

15-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.66M
↓ -37.7% —
Net Income Profit after all expenses
$-93.05M
↑ +6.0% —
FCF / Share Free cash flow per share
$-0.64
↑ +54.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
11
Cash Quality ↑
80

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 4 years · 15 quarters